These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 35229642)

  • 21. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.
    Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB
    J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.
    Adelakun AR; Turgeon RD; De Vera MA; McGrail K; Loewen PS
    BMJ Open; 2023 Apr; 13(4):e071907. PubMed ID: 37185198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
    Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
    J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology and outcomes of intracerebral hemorrhage associated with oral anticoagulation over 10 years in a population-based stroke registry.
    Gabriele F; Foschi M; Conversi F; Ciuffini D; De Santis F; Orlandi B; De Santis F; Ornello R; Sacco S
    Int J Stroke; 2024 Jun; 19(5):515-525. PubMed ID: 37997897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of stroke in patients with prior VKA or DOAC: A population-based real-world registry analysis.
    Mayer-Suess L; Rinner H; Lang W; Greisenegger S; Mikšová D; Gattringer T; Enzigner C; Sykora M; Vosko M; Mutzenbach JS; Ferrari J; Kiechl S; Knoflach M;
    Eur Stroke J; 2024 Jun; 9(2):418-423. PubMed ID: 38161290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Renal Function on Dosing of Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation.
    Shrestha S; Baser O; Kwong WJ
    Ann Pharmacother; 2018 Feb; 52(2):147-153. PubMed ID: 28856898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
    Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
    BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Underdosed Direct Oral Anticoagulants in Atrial Fibrillation Patients Reduce Stroke Severity and Improve Outcome.
    Naganuma M; Inatomi Y; Yonehara T; Nakajima M; Ueda M
    Cerebrovasc Dis; 2022; 51(4):473-480. PubMed ID: 34929687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe--a multicentric evaluation.
    Luger S; Hohmann C; Kraft P; Halmer R; Gunreben I; Neumann-Haefelin T; Kleinschnitz C; Walter S; Haripyan V; Steinmetz H; Foerch C; Pfeilschifter W
    Int J Stroke; 2014 Jul; 9(5):569-75. PubMed ID: 24828272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A meta-analysis.
    Yokoyama Y; Briasoulis A; Ueyama H; Mori M; Iwagami M; Misumida N; Takagi H; Kuno T
    J Thorac Cardiovasc Surg; 2023 Jun; 165(6):2052-2059.e4. PubMed ID: 34417050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation.
    Marzec LN; Wang J; Shah ND; Chan PS; Ting HH; Gosch KL; Hsu JC; Maddox TM
    J Am Coll Cardiol; 2017 May; 69(20):2475-2484. PubMed ID: 28521884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL; Hwang JM; Moser LR
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists.
    Sakai T; Motoki H; Fuchida A; Takeuchi T; Otagiri K; Kanai M; Kimura K; Minamisawa M; Yoshie K; Saigusa T; Ebisawa S; Okada A; Kitabayashi H; Kuwahara K
    Heart Vessels; 2022 Jul; 37(7):1232-1241. PubMed ID: 35064298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frailty, Cognitive Impairment, and Anticoagulation Among Older Adults with Nonvalvular Atrial Fibrillation.
    Mailhot T; McManus DD; Waring ME; Lessard D; Goldberg R; Bamgbade BA; Saczynski JS
    J Am Geriatr Soc; 2020 Dec; 68(12):2778-2786. PubMed ID: 32780497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct oral anticoagulants vs vitamin K antagonist on dementia risk in atrial fibrillation: systematic review with meta-analysis.
    Branco DR; Alves M; Severiano E Sousa C; Costa J; Ferreira JJ; Caldeira D
    J Thromb Thrombolysis; 2023 Oct; 56(3):474-484. PubMed ID: 37405677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.